ARDX
ARDELYX, INC.
NASDAQ · Healthcare · Biotechnology · US
$3.42
+1.18%Next report
Analyst consensus
- Next report date
- Oct 29, 2026
- EPS estimate
- -$0.03
- Revenue estimate
- $129.2M
Latest reported
- Last report date
- Aug 6, 2026
- EPS actual
- -$0.07
- EPS estimate
- -$0.07
- Revenue actual
- $120.9M
- Revenue estimate
- $121.0M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 5
- EPS misses (12Q)
- 6
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- -9.3%
- Revenue beats (12Q)
- 7
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $12
- PT range
- $9.00 – $15
- Analysts
- 5
5 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 6, 2026 | -$0.07 | -$0.07 | Miss -6.95% | $120.9M |
| Apr 30, 2026 | -$0.13 | -$0.15 | Miss -15.38% | $94.5M |
| Feb 19, 2026 | $0.02 | -$0.00 | Miss -108.35% | $125.2M |
| Oct 30, 2025 | -$0.06 | -$0.00 | Beat 93.32% | $110.3M |
| May 1, 2025 | -$0.10 | -$0.17 | Miss -70.00% | $74.1M |
| Feb 20, 2025 | $0.02 | $0.02 | In line | $116.1M |
| Oct 31, 2024 | -$0.05 | -$0.00 | Beat 93.14% | $98.2M |
| Aug 1, 2024 | -$0.10 | -$0.07 | Beat 30.00% | $73.2M |
| May 2, 2024 | -$0.13 | -$0.11 | Beat 15.38% | $46.0M |
| Feb 22, 2024 | -$0.09 | -$0.12 | Miss -33.33% | $34.4M |
| Aug 2, 2023 | -$0.12 | -$0.08 | Beat 33.33% | $22.3M |
| May 3, 2023 | -$0.11 | -$0.13 | Miss -18.18% | $11.4M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Oct 29, 2026